Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Kala Pharmaceuticals revenue
Kala Pharmaceuticals's revenue is $3.9 million.
What is Kala Pharmaceuticals's revenue?
- Kala Pharmaceuticals's revenue growth from 2019 to 2022 is -35.92%.
- Kala Pharmaceuticals has 192 employees, and the revenue per employee ratio is $20,270.
- Kala Pharmaceuticals's peak quarterly revenue was $3.3M in 2021(q1).
- Kala Pharmaceuticals peak revenue was $11.2M in 2021.
- Kala Pharmaceuticals annual revenue for 2021 was 11.2M, 76.67% growth from 2020.
- Kala Pharmaceuticals annual revenue for 2022 was 3.9M, -65.37% growth from 2021.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Kala Pharmaceuticals historical revenue
Kala Pharmaceuticals's peak revenue was $11.2M in 2021. The peak quarterly revenue was $3.3M in 2021(q1).
Kala Pharmaceuticals's revenue increased from $6.1m in 2019 to $3.9M currently. That's a -35.92% change in annual revenue.
Kala Pharmaceuticals annual revenue
Kala Pharmaceuticals annual revenue over time
| Fiscal year / year | Kala Pharmaceuticals revenue |
|---|---|
| 2019 | $6.1M |
| 2020 | $6.4M |
| 2021 | $11.2M |
| 2022 | $3.9M |
Rate Kala Pharmaceuticals' financial transparency
Kala Pharmaceuticals annual growth
Kala Pharmaceuticals saw the greatest revenue growth in 2021, when revenue increased by 76.67%.
Kala Pharmaceuticals had the lowest revenue growth in 2022, when revenue changed by -65.37%.
Kala Pharmaceuticals annual growth rate over time
| Year | Kala Pharmaceuticals growth |
|---|---|
| 2020 | 5%↑ |
| 2021 | 77%↑ |
| 2022 | -65%↓ |
Kala Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Kala Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | $1.4M | $2.1M | $1.5M | $1.2M |
| 2020 | $1.1M | $833,000 | $2.2M | $2.2M |
| 2021 | $3.3M | $3.1M | $3.1M | $1.9M |
| 2022 | $1.4M | $2.1M | $420,000 | - |
Kala Pharmaceuticals jobs nearby
Do you work at Kala Pharmaceuticals?
Did Kala Pharmaceuticals meet its revenue projections?
Kala Pharmaceuticals financing
Kala Pharmaceuticals received early financing of $2.0M on 2009-12-24.
| Series | Round size | Date |
|---|---|---|
| Series A | $2M | 12/2009 |
| Series Unknown | $3M | 11/2010 |
| Private Equity | $7.2M | 03/2012 |
| Series A | $11.5M | 02/2013 |
| Series B | $22.5M | 04/2014 |
| Series Unknown | $7.0M | 08/2015 |
| Series C | $68M | 04/2016 |
| Post Ipo Equity | $110M | 10/2018 |
| Post Ipo Equity | $134M | 04/2020 |
| Post Ipo Debt | $125M | 05/2021 |
| Post Ipo Equity | $16.1M | 11/2021 |
Kala Pharmaceuticals investors
| Investors | Security type |
|---|---|
| Polaris Partners | Private Equity |
| Lighthouse Capital Partners | Private Equity |
| Lux Capital | Private Equity |
| Third Rock Ventures | Private Equity |
| Crown Venture Fund | Series A |
| Polaris Partners | Series A |
| Lux Capital | Series A |
| Third Rock Ventures | Series A |
| Crown Venture Fund | Series B |
| Polaris Partners | Series B |
| Ysios Capital | Series B |
| Lux Capital | Series B |
| Third Rock Ventures | Series B |
| AbbVie Biotech Ventures Inc | Series B |
| Polaris Partners | Series C |
| Wellington Management | Series C |
| Vivo Capital | Series C |
| Lux Capital | Series C |
| Longitude Capital | Series C |
| OrbiMed Advisors | Series C |
| RA Capital Management | Series C |
| CAM Capital | Series C |
| Athyrium Capital Management LP | Post Ipo Equity |
| Oxford Finance LLC | Post Ipo Debt |
Search for jobs
Kala Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Kala Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Kala Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Kala Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Kala Pharmaceuticals. The data presented on this page does not represent the view of Kala Pharmaceuticals and its employees or that of Zippia.
Kala Pharmaceuticals may also be known as or be related to KALA PHARMACEUTICALS INC., Kala Pharmaceuticals, Kala Pharmaceuticals Inc, Kala Pharmaceuticals Inc. and Kala Pharmaceuticals, Inc.